An assessment of EGFR and HER2 inhibitors with structure activity relationship of fused pyrimidine derivatives for breast cancer: a brief review
Prasad Sanjay Dhiwar(Rajiv Gandhi University of Health Sciences), Ganesh S. Andhale, Lalmohan Maji, Sindhuja Sengupta, Abhishek Ghara(Dr. Reddy's Laboratories (United States)), Gurubasavaraja Swamy Purawarga Matada(Rajiv Gandhi University of Health Sciences), Ekta Singh(Rajiv Gandhi University of Health Sciences), Rohit Pal(Drug Discovery Laboratory (Norway))
Cited by 28
Related Papers
Molecular docking and molecular dynamic studies: screening of phytochemicals against EGFR, HER2, estrogen and NF-KB receptors for their potential use in breast cancer
|Journal of Biomolecular Structure and Dynamics|2021|37
DDR1 and DDR2: a review on signaling pathway and small molecule inhibitors as an anticancer agent
|Medicinal Chemistry Research|2021|35
Benzothiazole a privileged scaffold for Cutting-Edges anticancer agents: Exploring drug design, structure-activity relationship, and docking studies
|European Journal of Medicinal Chemistry|2024|32
An updated literature on BRAF inhibitors (2018–2023)
|Molecular Diversity|2023|24
Management of COVID-19-induced cytokine storm by Keap1-Nrf2 system: a review
|Inflammopharmacology|2021|21